www.verygoodnewsisrael.blogspot.com
Israel is always in the news. Hardly a day goes by without shrieking headlines about protests, counter protests and terror. That is striking considering that in 2023 the population is 9,174, 520 people with a global ranking of 98. Per capita there is not a single country with such dazzling research and development of medicine, technology, economy, agriculture, and social institutions which enhance the life and prospects of billions of citizens throughout the globe. Furthermore, Israel’s unique cuisine and its beautiful beaches, arts, music and theater enchant tourists from all over the world including formerly hostile Arab/Moslem nations.
Fortunately, all the foregoing is catalogued by Michael Ordman almost every week. rsk
ISRAEL’S MEDICAL ACHIEVEMENTS
Whole genome cancer detection. It wasn’t long ago since the genome was fully decoded. Now, Israel’s C2i Genomics (see here previously) has teamed up with Tel Aviv’s Sourasky (Ichilov) Medical Center take blood test data and perform whole genome minimal residual disease (MRD) testing to detect recurring cancer early.
https://www.israel21c.org/ai-cancer-startup-collaborates-with-top-israeli-hospital/ https://c2i-genomics.com/
Biopsy the cells. (TY Atid-EDI) Israel’s MetaSight Diagnostics is developing fast, low-cost mass spectrometry to perform vast amounts of serum biopsies of the metabolome (molecules in a cell). These can detect cancer, liver disease, cardiovascular and neurological diseases etc. MetaSight is working with KSM (Maccabi’s R&D).
https://metasightdx.com/ https://www.youtube.com/watch?v=6wsHb4l7HXc
Light-activated cancer treatment gets US support. (TY Atid-EDI) Israel’s ImPact Biotech has received Orphan treatment designation from the US FDA for its Padeliporfin VTP in Pancreatic Cancer. ImPact stands for IMmune Photo Activated Cancer Treatment and VTP is Vascular Targeted Photodynamic therapy.
https://impactbiotech.com/impact-biotech-receives-fda-orphan-drug-designation-for-padeliporfin-vtp-in-pancreatic-cancer/ https://impactbiotech.com/
US NIH funds Israeli radiation therapy. The U.S. National Institutes of Health has granted Israel’s Pluri (previously Pluristem) $4.2 million to develop its PLX-R18 (see here) as a treatment for Hematopoietic Acute Radiation Syndrome – a deadly disease that can result from nuclear disasters and radiation exposure.
https://pluri-biotech.com/wp-content/uploads/2023/07/1689056470_PLUR_NIAID_ARS_PR_FINAL-2.pdf
https://pluri-biotech.com/wp-content/uploads/2023/08/Pluri_PR_re_BMT_Article_FINAL_accessible.pdf
Transforming clinical best practices. (TY OurCrowd) Israel’s Quai.MD is developing an AI- platform that improves hospital patient care, reduces costs and saves doctors’ time. The process is tailored to the patient and hospital. Partners include Mayo Clinic & MUSC. Initial focus is the diagnosis of patients with chest pain.
https://nocamels.com/2023/08/ai-platform-helps-diagnose-chest-pain-swiftly-and-accurately/ https://quai.md/
https://www.youtube.com/watch?v=Tiv_hbQY8Is
11,000 focused ultrasound procedures. (TY OurCrowd) A 5-year study of patients has proved the success of the focused ultrasound treatment from Israel’s Insightec (see here previously). It improved quality of life with no progressive or delayed complications. Insightec’s technology has been used 11,000+ times globally.
https://www.prnewswire.com/il/news-releases/focused-ultrasound-treatment-is-proven-an-effective-treatment-to-curb-tremor-for-at-least-five-years-898536012.html
Brain stimulation eases ADHD symptoms. In a small clinical study, Israeli and UK researchers found non-invasive brain stimulation improved the condition of 55% of unmedicated ADHD children aged 6-12. Only 17% of the placebo control group improved. 64% of the treated children retained the improvement weeks later.
https://en.huji.ac.il/news/hope-children-adhd-new-study-finds-non-invasive-brain-stimulation-treatment-can
Next gen blood test device gets US approval. (TY OurCrowd) The US FDA has approved the upgraded 15-minute bacteria vs virus diagnostic blood test device from Israel’s MeMed (see here previously). The new MeMed BV is now suitable for urgent care centers, as it avoids the clotting and spinning process of the original.
https://www.me-med.com/press_release/fda-clears-memed-bv-direct-from-whole-blood/
Approval for smart colonoscopy device. (TY Atid-EDI) MAGENTIQ-COLO from Israel’s MAGENTIQ-EYE (see here previously) has been cleared by the US FDA and Israel’s AMAR, and received Europe’s CE Mark. The AI-assisted device is significantly more efficient in detecting adenomas (pre-cancerous polyps).
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K223473 https://www.magentiq.com/
https://vimeo.com/540882393 https://www.youtube.com/watch?v=J4HtDuXWAqo
Re-educate your muscles. Israel’s Neuro Trigger is developing a powered muscle stimulator to repeatedly contract muscles to increase their range of motion and prevent retardation. Neuro trigger has received a BIRD grant (see below) to develop an eyelid pacemaker that restores blinking to those with facial paralysis.
https://www.nt-med.com/
Remote health care for Madrid region. (TY Atid-EDI) Israel’s Essence SmartCare (see here previously) has won a contract from the Community of Madrid governmental region. Essence will use its digital AI systems to replace outdated analog remote care services for 100,000 senior citizens and disabled individuals.
https://www.prnewswire.com/news-releases/the-community-of-madrid-selects-essence-smartcare-to-provide-advanced-remote-care-technologies-for-senior-and-disabled-citizens-301873901.html